WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: 20131201_Zortress_cmap, Characteristics include Living, loss to follow-up is defined by last day of contact was prior to study Day 316, patients may discontinue Study Medication, loss to follow-up do(es) not include biopsy proven acute rejection (bpar), biopsy grade can be IIB, mouth ulcerations is an adverse event, Primary Endpoint defined as Efficacy Failure, Study Medication due to death, M-TOR inhibitors can cause pneumonitis, biopsy grade can be IB, blood and lymphatic system disorders are an adverse event, patients are denoted as loss to follow-up, metabolic syndrome is linked to patient loss, Study Phase due to Withdrawl of Consent, graft loss can be assessed at 6 months, M-TOR inhibitors are associated with proteinuria, infections and infestations are an adverse event, cardiovascular risk is associated with hyperlipidemia, death can be assessed at 12 months, loss to follow-up do(es) not include death